CLOs on the Move

Blue Cross Blue Shield of Kansas

www.bcbsks.com

 
The largest health insurer in the state of Kansas. As a mutual insurance company, BCBSKS is owned by its policyholders. Its board of directors consists of Kansans from different areas of the state, 16 policyholders who bring to the table practical experience in business, medicine, hospital administration and education. Day-to-day operations are directed by a nine-person steering committee under the guidance of the company’s president/CEO. Customers and health care professionals have a voice in company activities through numerous advisory and liaison committees, as well as focus groups and surveys. BCBSKS is a financially secure, billion dollar company that contributes to ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.bcbsks.com
  • 1133 SW Topeka Boulevard
    Topeka, KS USA 66629
  • Phone: 785.291.7000

Executives

Name Title Contact Details
Clay Britton
Vice President of Legal and Compliance Services and General Counsel Profile
Dan Roehler
Chief Compliance Officer Profile
Matt All
President and Chief Executive officer Profile
Scott Raymond
Vice President of Legal Services and General Counsel Profile

Similar Companies

Ability First Inc

Ability First Inc is a Poughkeepsie, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palmetto Health

Palmetto Health is South Carolina's largest and most comprehensive healthcare resource. In our progressive environment, the latest technology and treatment protocols go hand-in-hand with quality patient care.

United Medical

United Medical is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Well Point

Well Point is a Half Moon Bay, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.